At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 100 enrolled
Drug / intervention
ropivicaine 0.2%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Regional Block for Postoperative Free Flap Care
In Brief
A Phase 4 clinical trial evaluating ropivicaine 0.2% for Pain Management. Completed, enrolled 100 participants across 1 site.
Detailed Summary
The purpose of this protocol is to evaluate the safety and efficacy of regional anesthesia for head and neck patients undergoing microvascular free flap reconstruction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain Management
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedSep 2019
Enrollment StartJan 2020
Primary CompletionMar 2022
TodayJul 2026
First PostedSep 6, 2019
Enrollment StartJan 13, 2020
Primary CompletionMar 1, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.8 years ago
Interventions
ropivicaine 0.2%drug
2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus nerve block for forearm free flap patients.